DSM B.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
21 dec 2010 - 07:44
Statutaire naam
DSM B.V.
Titel
DSM to acquire Martek to add new Nutrition growth platform
Bericht
DSM (NYSE Euronext: DSM KON) to offer US$31.50 for each share of Martek Biosciences Corporation (NASDAQ: MATK) in an all-cash transaction (through a tender offer)
Total consideration of US$1,087 million (about EUR829 million)
Offer price represents 35% premium to Martek`s closing share price on December 20, 2010
Martek Board of Directors recommends the offer
Acquisition adds new growth platform for natural, healthy Polyunsaturated Fatty Acids (PUFAs) nutrition ingredients (Omega-3 DHA and Omega-6 ARA)
PUFAs are clinically proven to have important human health benefits. Martek is a leader in this field with strong positions, especially in Infant Formula Nutrition applications
Datum laatste update: 09 mei 2025